HLX-53

N/A

Report date: 2025/10/30 14:38:51

Base Information

Drug NameHLX-53
Drug Alias Nameanti-TIGIT Fc fusion protein (Shanghai Henlius Biologics)抗TIGIT的Fc融合蛋白（上海复宏汉霖）HLX-53HLX53
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitors
TargetsT cell immunoglobulin and ITIM domains
Therapy Area/IndicationsSolid tumoursCarcinoma, HepatocellularLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Henlius Biologics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Henlius Biologics Co LtdShanghai Henlius Biotech IncShanghai Henlius Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, HepatocellularLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A